US2018215822A1PendingUtilityA1
Methods and compositions for inhibiting cd32b expressing cells
Est. expiryMay 30, 2027(~0.8 yrs left)· nominal 20-yr term from priority
A61P 37/06A61P 37/08A61P 29/00A61P 3/10A61P 35/00A61P 19/02A61P 1/00C07K 2317/31C07K 16/2851C07K 16/2878C07K 16/283C07K 16/00C07K 2317/53C07K 2317/72C07K 2317/71C07K 16/2803C07K 2317/524C07K 2317/24C07K 2317/77C07K 2317/92C07K 2317/732C07K 2317/52C07K 2317/734C07K 2317/76C07K 2317/73A61K 2039/505
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . (canceled)
3 . A nucleic acid encoding an Fc variant comprising at least amino acid modifications S267E and L328F as compared to a human Fc polypeptide, wherein numbering is according to the EU index according to Kabat.
4 . An expression vector comprising the nucleic acid of claim 3 .
5 . A host cell comprising the vector of claim 4 .
6 . A method of treating an autoimmune disease comprising administering a protein comprising an Fc variant comprising at least amino acid modifications S267E and L328F as compared to a human Fc polypeptide, wherein numbering is according to the EU index according to Kabat.
7 . (canceled)
8 . A nucleic acid encoding a heavy chain an antibody, the heavy chain comprising an Fc variant comprising at least amino acid modifications S267E and L328F as compared to a human Fc polypeptide, wherein numbering is according to the EU index according to Kabat.
9 . An expression vector comprising the nucleic acid of claim 8 .
10 . A host cell comprising the vector of claim 9 .Join the waitlist — get patent alerts
Track US2018215822A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.